Back to top
more

Dr. Reddys Laboratories (RDY)

(Real Time Quote from BATS)

$78.38 USD

78.38
163,727

-2.06 (-2.56%)

Updated Jul 16, 2024 03:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)

Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Top Ranked Momentum Stocks to Buy for March 20th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 20th

Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3

Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.

Dr. Reddy's (RDY) Earnings Rise in Q3, Sales Increase Y/Y

Dr. Reddy???s earnings and sales increase year over year in the third quarter of fiscal 2019.

Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?

Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.

Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility

Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.

Sweta Killa headshot

Top-Ranked Sector ETFs & Stocks to Buy for 2019

Investors could be well served by ETFs and stocks from top-ranked sectors.

VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster

Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.

Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar

Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.

The Zacks Analyst Blog Highlights: Internet Initiative Japan, Sony, Ingersoll-Rand, HDFC Bank and Dr. Reddy's Laboratories

The Zacks Analyst Blog Highlights: Internet Initiative Japan, Sony, Ingersoll-Rand, HDFC Bank and Dr. Reddy's Laboratories

Generic Industry on Path to Recovery: 3 Hot Picks for 2019

The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.

Swarup Gupta headshot

5 ADRs That More Than Doubled the S&P 500 in 2018

Japan, Ireland and India's economies offer a glimmer of hope since they are expected to perform well in 2019

Highlighted as Zacks Bull and Bear of the Day Dr. Reddy???s Laboratories, Dillard???s, Facebook, Netflix and Amazon

Highlighted as Zacks Bull and Bear of the Day Dr. Reddy???s Laboratories, Dillard???s, Facebook, Netflix and Amazon

David Borun headshot

Bull of the Day: Dr. Reddy's Laboratories

This vertically integrated pharmaceutical company produces exactly the drugs the world needs most.

Zacks.com featured highlights include: Abercrombie, Dr. Reddy???s, Cree, Otter and Shenandoah

Zacks.com featured highlights include: Abercrombie, Dr. Reddy???s, Cree, Otter and Shenandoah

Bet on These 5 Low-Beta Stocks to Fight Market Volatility

We develop an investment strategy that shows low-beta stocks can be rewarding if some parameters are considered.

Generic Drugmakers Down on Allegations of Price Fixing

An article in The Washington Post levels charges of price fixing against several generic drugmakers, driving their shares down.

The Zacks Analyst Blog Highlights: Anthem, HCA, Dr. Reddy's and UnitedHealth

The Zacks Analyst Blog Highlights: Anthem, HCA, Dr. Reddy's and UnitedHealth

Tirthankar Chakraborty headshot

Healthcare Takes Wall Street Lead: 4 Picks

Continuous innovation and research in the field of biotechnology and an increasingly aged population in the United States are helping whet appetite for healthcare shares.

Zacks.com highlights: Marcus, Papa Murphy's Holdings, Dr. Reddy's Laboratories, Tesla and Spirit Airlines

Zacks.com highlights: Marcus, Papa Murphy's Holdings, Dr. Reddy's Laboratories, Tesla and Spirit Airlines

Lilly (LLY) Hits Fresh High: Is There Still Room to Run?

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

5 Low-Beta Stocks to Weather Market Volatility

We create a strategy which shows that handsome returns can also be generated from less risky stocks.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for November 26th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment

Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.

Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2

Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.